HGHクリスタルMD?の口腔内環境改善効果—非盲検前後比較試験—

摘要

Objective We aimed to investigate the improvement of the oral environment in healthy Japanese adults following ingestion of HGH crystal MD?. Methods Two open-label comparative studies were conducted in November 2018 (preliminary trial) and March 2019 (main trial) in healthy Japanese adults who were not aware of dental caries (n=11,n = 27, respectively). HGH crystal MD was taken orally 3 times daily ； the intervention period was 1 week (preliminary trial) and 4 weeks (main trial).Assessments of periodontal disease-related bacteria, evaluation of subjective symptoms, peripheral hematology tests, and oral examinations were perfonned before and 1 week (preliminary trial) or 4 weeks (main trial) after the ingestion of HGH crystal MD?. Safety was monitored throughout. Results Eleven participants for the preliminary trial and 25 participants for the main trial were included in the analysis. In both trials, Tannerella forsythensis, a periodontopathy-related red-complex bacterium, was significantly decreased after ingestion compared with before ingestion (P<0.05). Subjective symptom evaluation showed significant improvements in oral odor, gum swelling, tooth roughness, mouth discomfort, mouth dryness, and stickiness in both trials (P < 0?05). No subjects experienced any change in caries progression during the study, and no ingestionassociated adverse events were observed. Conclusions HGH crystal MD? significantly decreased T. forsythensis, improved subjective oral cavity symptoms, and was found to be safe for the treatment of periodontal disease in this group of patients. Trial registration UMIN-CTR: UMIN000034948 (preliminary trial),UMIN000035393 (main trial) Foundation Autobahn Co. Ltd.